SUMF1

Across TCGA pan-cancer cohorts, SUMF1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SUMF1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SUMF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUMF1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where SUMF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.416	0.991	.001	45	view →
GBM	DFS	Tertile	All	0.637	0.830	.012	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.388	1.000	.007	7	view →
HNSC	DFS	Quartile	II,III,IV	0.988	0.869	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SUMF1–PDAC (DFS)

Open the PDAC breakdown →